AIM AIM ImmunoTech Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 946644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.8%
TTM net income YoY10.3%
TTM EPS YoY93.4%
Revenue 3-yr CAGR-22.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,800.0%
Net margin-15,526.4%
FCF margin—
EBITDA margin-11,853.8%
Returns
ROE-2,828.6%
ROA-185.4%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets27.4%
Debt / equity0.41x
Current ratio2.75x
Interest coverage-9.33x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $22,000 | $26,000 | $22,000 | $21,000 | $26,000 | $25,000 | $16,000 | $45,000 |
| R&D expense | $846,000 | $589,000 | $482,000 | $1.06M | $607,000 | $1.17M | $1.08M | $1.66M |
| SG&A expense | $2.13M | $2.94M | $1.76M | $1.87M | $1.80M | $1.49M | $2.54M | $4.23M |
| Operating income | -$2.96M | -$3.51M | -$2.23M | -$2.95M | -$2.45M | -$2.65M | -$3.62M | -$5.86M |
| Interest expense | $259,000 | $295,000 | $304,000 | $391,000 | $581,000 | $149,000 | $124,000 | $132,000 |
| Net income | -$3.14M | -$3.79M | -$3.02M | -$4.17M | -$3.28M | -$2.79M | -$3.71M | -$5.97M |
| EBITDA | -$2.68M | -$2.95M | -$2.22M | -$2.94M | -$2.27M | -$2.64M | -$3.61M | -$5.85M |
| EPS (basic) | -0.21 | -0.43 | -0.69 | — | -1.57 | -3.68 | -0.05 | — |
| EPS (diluted) | -0.21 | -0.43 | -0.69 | — | -1.57 | -3.68 | -0.05 | — |
| Weighted avg. shares (diluted) | 32.49M | 17.12M | 4.35M | — | 2.09M | 759,289 | 703,298 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.89M | $9.90M | $5.82M | $2.98M | $2.35M | $476,000 | $898,000 | $1.70M |
| Short-term investments | $61,000 | $64,000 | $63,000 | $62,000 | $62,000 | $359,000 | $1.35M | $2.28M |
| Receivables | — | — | — | $7,000 | — | — | — | — |
| Current assets | $7.34M | $10.43M | $6.21M | $3.29M | $2.58M | $1.02M | $2.58M | $4.18M |
| PP&E, net | $49,000 | $54,000 | $62,000 | $71,000 | $80,000 | $89,000 | $98,000 | $108,000 |
| Intangibles | $1.76M | $1.71M | $1.66M | $1.66M | $2.04M | $2.17M | $2.27M | $2.59M |
| Total assets | $9.75M | $12.73M | $8.59M | $5.78M | $5.49M | $4.13M | $6.25M | $8.61M |
| Current liabilities | $2.67M | $4.95M | $6.14M | $6.22M | $4.04M | $10.39M | $9.77M | $9.54M |
| Short-term debt | $1.44M | $3.62M | $4.00M | $3.55M | $1.88M | $2.29M | $1.95M | $2.31M |
| Long-term debt | $1.44M | $3.62M | $210,000 | $927,000 | — | $2.72M | $2.39M | $2.81M |
| Total debt | $2.87M | $7.24M | $4.21M | $4.48M | — | $5.01M | $4.34M | $5.11M |
| Total liabilities | $2.67M | $4.99M | $6.46M | $15.56M | $11.57M | $10.68M | $10.11M | $9.93M |
| Shareholders' equity | $7.08M | $7.74M | $2.12M | -$9.78M | -$6.08M | -$6.55M | -$3.86M | -$1.32M |
| Net debt | -$4.01M | -$2.66M | -$1.60M | $1.49M | — | $4.54M | $3.44M | $3.41M |
| Shares outstanding | 39.89M | 28.99M | 8.22M | 3.07M | 2.76M | 764,188 | 72.29M | 655,262 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.93M | -$4.59M | -$2.72M | -$1.99M | -$5.08M | -$1.53M | -$2.36M | -$3.96M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$3.96M |
| Investing cash flow | -$83,000 | -$112,000 | -$37,000 | -$95,000 | $296,000 | $754,000 | $898,000 | $3.70M |
| Financing cash flow | $1,000 | $8.79M | $5.59M | $2.72M | $6.65M | $355,000 | $660,000 | $1.04M |
| Depreciation & amortization | $281,000 | $562,000 | $9,000 | $9,000 | $182,000 | $9,000 | $10,000 | $9,000 |
| Stock-based compensation | — | $0 | $0 | $0 | $0 | $0 | $60,000 | $196,000 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.